Novakand Pharma AB Company Description

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally.

The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer.

It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.

The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025.

Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.

Novakand Pharma AB (publ)

Country	Sweden
Founded	2010
Industry	Biological Products, Except Diagnostic Substances
Employees	5
CEO	Peter Selin

Contact Details

Address: Karolinska Institutet Science Park Solna, 171 65 Sweden
Phone	46 8 50 12 60 80
Website	novakand.com

Stock Details

Ticker Symbol	3EE0
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Peter Selin	Chief Executive Officer